Bibliografía del artículo
1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin 58:71-96, 2008.
2. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330-353, 2004.
3. Fentiman IS, Tirelli V, Monfardini S, et al. Cancer in the elderly: why so badly treated? Lancet 28:1020-1022, 1990.
4. Balducci L. Geriatric oncology: challenges for the new century. Eur J Cancer 36:1741-1754, 2000.
5. Yancik R, Ganz PA, Varricchio CG, Conley B. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol 19:1147-1151, 2001.
6. Janssen-Heijnen MLG, Schipper RM, Razenberg PPA, Crommelin MA, Coeberg JW. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 21, 105-113, 1998.
7. Ershler WB, Long DL. Aging and cancer: issues of basic and clinical science. J Natl Cancer Inst 89:1489-1497, 1997.
8. Turner N, Scarpace PJ, Lowental DT. Geriatric pharmacology: basic and clinical considerations. Ann Rev Pharmacol Toxicol 32:271-302, 1992.
9. Mayersohn M. Pharmacokinetics in the elderly. Environ Health Perspect 102(Suppl.11):119-124, 1994.
10. Litchman SM, Villani G. Chemotherapy in the elderly: pharmacologic considerations. Cancer Control 7:548-556, 2000.
11. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: An Italian Group for Geriatric Oncology Study. J Clin Oncol 20:494-502, 2002.
12. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146-M156, 2001.
13. Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 49:1691-1699, 2001.
14. Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the Multicenter Italian Lung cancer in the Elderly Study. J Clin Oncol 23:6865-6872, 2005.
15. Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66-72, 1999.
16. Rossi A, Maione P, Colantuoni G, et al. The role of chemotherapy in the treatment of advanced non-small cell lung cancer elderly patients. Cancer Ther 5:77-78, 2007.
17. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 18:2529-2536, 2000.
18. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomized trial. J Natl Cancer Inst 95:362-372, 2003.
19. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJOG 9904). J Clin Oncol 24:3657-3663, 2006.
20. Gridelli C, Maione P, Rossi A. Single-agent chemotherapy for the treatment of elderly patients with advanced non-small-cell lung cancer: What is the best drug? J Clin Oncol 25:1444-1445, 2007.
21. Rossi A, Maione P, Gridelli C. Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients. Expert Opin Drug Saf 4:1051-1067, 2005.
22. Perrone F, Gallo C, Gridelli C. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:1029-1030, 2002.
23. Gridelli C, Maione P, Illiano A, et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non-small-cell lung cancer: the MILES-2p studies. J Clin Oncol 25:4663-4669, 2007.
24. Biesma B, Wymenga MN, Vincent AD, et al. A randomized phase III study of carboplatin-gemcitabine (CG) versus carboplatin-paclitaxel (CP) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) with emphasis on geriatric assessment and quality of life (QoL): The NVALT-3 study. J Thor Oncol 2(Suppl.4):S667-S668 (abstr P2-239), 2007.
25. Scagliotti G, Rossi A, Novello S, et al. Gefitinib (ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 22(14S):636s (abstr 7081), 2004.
26. Jackman D, Yeap YB, Lindeman IN, et al, Phase II clinical trial of chemotherapy naïve patients = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 25:760-766, 2007.
27. Crinò L, Zatloukal P, Reck M, et al. Gefitinib (IRESSA) verus viorelbine in chemo-naive elderly patients with advanced non small cell lung cancer (INVITE): a randomized phase II study. J Thor Oncol 2:S341 (abstr. B3-04), 2007.
28. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 26:60-65, 2008.